Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative p-furoylamphenmulin against Mycoplasma gallisepticum in vivo in chickens.

ABSTRACT: Mycoplasma gallisepticum (M. gallisepticum, MG) is the primary pathogen of chronic respiratory disease (CRD) in chickens and leads to pneumonia and air sacculitis in infected chickens and a corresponding economic loss for the poultry industry. The pleuromutilins have excellent anti-mycoplasmal activity and we evaluated the in vivo activity of a new derivative 22-((4-((2-furan-1-yl)acetamido)phenyl)thio) deoxypleuromutilin (p-furoylamphenmulin) against M. gallisepticum. A plasma pharmacokinetic (PK) study and an in vivo pharmacodynamic (PD) study of p-furoylamphenmulin were performed using an M. gallisepticum-infected chicken model. Based on the PK/PD results, a preliminary recommended dose was calculated. The minimum inhibitory concentration (MIC) of p-furoylamphenmulin against M. gallisep

SUBMITTER: Xia X 

PROVIDER: S-EPMC12142322 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature